Navigation Links
Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
Date:8/29/2012

HORSHAM, Pa., Aug. 30, 2012 /PRNewswire/ -- Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.  Daratumumab (HuMax®-CD38) is a human CD38 monoclonal antibody currently in Phase I/II studies in relapsed, refractory multiple myeloma. 

"Janssen was one of the first companies to recognize the power and promise of monoclonal antibodies and today is a world leader in biologics.  We look forward to applying that same expertise to daratumumab to help meet the needs of patients with multiple myeloma," said William N. Hait, M.D., Ph.D., head of Janssen Research & Development, LLC.  "Daratumumab is an exciting, innovative compound, and we are delighted to add it to our portfolio."

Under terms of the agreement, Genmab will grant Janssen an exclusive worldwide license to develop and commercialize daratumumab as well as a back-up CD38 human antibody.  Janssen has made an upfront payment and will make additional payments based upon the achievement of certain development, regulatory and sales milestones.  Genmab will be responsible for completing the GEN501 and GEN503 Phase I/II trials.  Janssen will be responsible for all other development, clinical and regulatory filing activities.  In addition, as part of the agreement, Johnson & Johnson Development Corporation, an affiliate of Janssen, will make an equity investment in Genmab.

The transaction is subject to customary closing conditions, including approval by the Danish Financial Supervisory Authority and clearance by the U.S. antitrust authorities.

About Daratumumab
Daratumumab is a human monoclonal antibody (mAb) with broad spectrum cytotoxic activity.  It targets the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.  It is currently in Phase I/II trials for multiple myeloma and has potential applicability against other malignancies on which CD38 is expressed.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., rheumatoid arthritis, intestinal bowel disease (IBD) and psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).

Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  The viewer is cautioned not to rely on these forward-looking statements.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Biotech, Inc., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; impact of business combinations; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; and changes in behavior and spending patterns or financial distress of purchasers of health care products and services.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Neither Janssen Biotech, Inc., nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.


'/>"/>
SOURCE Janssen Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
4. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
5. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
6. New Stroke Drug from ZZ Biotech Produced by Laureate Biopharma
7. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
8. German-based Contract Research Organization Verum.de Opens US Office to Expand Clinical Study Services in Central and Eastern Europe for American Pharma and Biotech
9. Antibiotics and Biotechnology Take Center Stage at Food Dialogues Event
10. Save Up To 25% on International Biotech and Healthcare, and Pharmaceutical Conferences by Registering Through GII
11. Kibow Biotech Marks Its Continued Growth with Relocation to Larger Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... 2017  A recent study published in the ... light as a means of disinfection anesthesia workstations ... bioburden on anesthesia workstations. In the study, UVC ... medical equipment surfaces contaminated with three (3) organisms ... study further validates the body of literature supporting ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017  The ... Clinical and Scientific Meeting— OBP Medical , a leading ... announced the launch of a new extra-small size and ... ER-SPEC vaginal specula. Already available in small, ... sizes makes OBP Medical,s line of single-use lighted specula ...
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
Breaking Medicine Technology:
(Date:5/24/2017)... Birmingham, Clarkston, Lake Orion, Michigan (PRWEB) , ... ... ... Endometriosis is a disease affecting the female reproductive tract in which ... itself on the pelvic structures causing inflammation and pain. Patients experiencing painful ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... practice is offering holistic pediatric dentistry options for its patients on Long Island, ... the patient’s entire physical well being, and is one of the biggest trends ...
(Date:5/24/2017)... West Orange, NJ (PRWEB) , ... May 24, 2017 , ... ... ingredients for avoiding back injury when either lifting weights for strength training and exercise ... Atlantic Spine Center . , “Body position is everything,” Dr. Chang says. “Improper ...
(Date:5/23/2017)... ... 23, 2017 , ... Allegheny Health Network and the Alexis ... for Women’s Behavioral Health at West Penn Hospital , a unique facility that ... from pregnancy-related depression. Construction of the Center is underway with a scheduled opening ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... (PHM) technology and a 2017 Best in KLAS category winner, has named Daniel ... position to extend and enhance its technology platform and product offerings,” says Justin ...
Breaking Medicine News(10 mins):